Multinational enterprises (MNEs) can contribute to the building of civil society in the developing world and have an enlightened self-interest in doing so. The development of civil society solidifies and levels the playing field, thereby protecting longer-term investment from unpredictable social backlash and arbitrary state intervention. At the same time, the reactions of host country governments to MNE-civil society collaboration may vary from benevolent to hostile, depending on the type of collaborative activities involved. This article provides a framework for MNE managers to anticipate when such activities are likely to be greeted with open arms as opposed to when MNE managers need to tread lightly.

The need to play catch-up in biotechnology has led Germany and Japan to adopt novel technology policies. Whereas policies to assist domestic industries have traditionally been geared toward incumbent firms, current trends revolve around "science entrepreneurship"--reforms in the national R&D system and targeted incentives for biotechnology scientists to file patents and start up their own firms. Japan, in particular, has recognized that catching up with the United States in basic science and in the commercialization of scientific research represents a kind of final frontier.